Hercules Capital Inc  

(Public, NYSE:HTGC)   Watch this stock  
Find more results for NASDAQ:HTGC
+0.04 (0.30%)
Sep 26 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 13.27 - 13.41
52 week 9.88 - 14.00
Open 13.34
Vol / Avg. 394,225.00/263,210.00
Mkt cap 996.93M
P/E 23.46
Div/yield 0.31/9.30
EPS 0.57
Shares 74.84M
Beta 1.01
Inst. own 42%
Nov 3, 2016
Q3 2016 Hercules Capital Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 27, 2016
Hercules Capital Inc at JMP Securities Financial Services and Real Estate Conference - 1:00PM EDT - Add to calendar
Aug 4, 2016
Q2 2016 Hercules Capital Inc Earnings Call
Aug 4, 2016
Q2 2016 Hercules Capital Inc Earnings Release
Jul 7, 2016
Hercules Capital Inc Annual Shareholders Meeting
Jul 6, 2016
Hercules Technology Growth Capital Inc Annual Shareholders Meeting (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 21.76% 27.31%
Operating margin 53.64% 46.78%
EBITD margin - 46.90%
Return on average assets 2.79% 3.27%
Return on average equity 5.12% 6.02%
Employees 63 -
CDP Score - -


400 Hamilton Ave Ste 310
PALO ALTO, CA 94301-1805
United States - Map
+1-650-2893060 (Phone)
+1-650-4739194 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Hercules Capital, Inc., formerly Hercules Technology Growth Capital, Inc., is a specialty finance company. The Company is focused on providing senior secured venture growth loans to venture capital-backed companies in a range of technology, life sciences and sustainable and renewable technology industries. The Company is an internally managed, non-diversified, closed-end investment company. The Company focuses its investments in companies active in the technology industry sub-sectors characterized by products or services, including computer software and hardware; networking systems; semiconductors; semiconductor capital equipment; information technology infrastructure or services; Internet consumer and business services; telecommunications; telecommunications equipment, and media. Within the life science sub-sector, the Company focuses on medical devices, bio-pharmaceutical, drug discovery, drug delivery, healthcare services and information systems companies.

Officers and directors

Manuel A. Henriquez Chairman of the Board, President, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark Robert Harris CPA Chief Financial Officer
Age: 45
Bio & Compensation  - Reuters
Scott Bluestein Chief Investment Officer
Age: 36
Bio & Compensation  - Reuters
Melanie Grace Chief Compliance Officer, General Counsel
Age: 46
Bio & Compensation  - Reuters
Andrew Olson Vice President - Finance, Senior Controller
Age: 32
Bio & Compensation  - Reuters
Jennifer McKay Vice President of Human Resources
Bio & Compensation  - Reuters
Allyn C. Woodward Jr. Lead Independent Director
Age: 74
Bio & Compensation  - Reuters
Robert P. Badavas Independent Director
Age: 62
Bio & Compensation  - Reuters
Thomas J. Fallon Independent Director
Age: 54
Bio & Compensation  - Reuters
Rodney A. Ferguson Ph.D. J.D. Independent Director
Age: 55
Bio & Compensation  - Reuters